Replimune Group, Inc. (NASDAQ:REPL) Expected to Post Q2 2025 Earnings of ($0.77) Per Share

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for Replimune Group in a research note issued to investors on Tuesday, September 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.13) per share. HC Wainwright also issued estimates for Replimune Group’s Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.16) EPS.

A number of other equities research analysts have also commented on the company. JPMorgan Chase & Co. decreased their price target on Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Barclays increased their target price on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Wedbush restated an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $16.20.

Replimune Group Stock Performance

NASDAQ REPL opened at $10.38 on Thursday. Replimune Group has a 1-year low of $4.92 and a 1-year high of $19.44. The company has a 50 day moving average of $10.00 and a 200-day moving average of $8.33. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market cap of $709.16 million, a price-to-earnings ratio of -3.20 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10.

Insider Activity

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the business. Millennium Management LLC lifted its stake in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after acquiring an additional 1,679,553 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after acquiring an additional 276,596 shares during the last quarter. Finally, Clearbridge Investments LLC acquired a new position in Replimune Group during the fourth quarter valued at approximately $2,282,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.